There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight gain, in an early sign that the drugmaker may look to broaden the rollout of the medications beyond obese patients.

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized on the pinch, are tumbling.

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes and weight loss drugs are gaining market share as manufacturing continues to expand,

WeightWatchers said on Tuesday it would offer compounded form of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs, sending its shares up 13% in early trading. Soaring demand for weight-loss drugs such as

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound,